BALTIMORE, June 19 /PRNewswire/ -- Cognate Therapeutics, Inc. today announced it has changed its name to Cognate BioServices, Inc. As a leader in the provision of biotechnology services, a name change better reflects the company's focus and achievements in providing product development and cGMP manufacturing services to organizations in the regenerative medicine space working on cell therapies.
President and Chief Operating Officer Dr. Alan K. Smith said, "The name Cognate BioServices emphasizes our business focus on the provision of services related to the development and cGMP manufacturing of cell-based therapeutics. We are taking advantage of our unique and extensive experience base and facilities which allow us to provide a spectrum of services, ranging from preclinical process development and scale-up, through complete cGMP manufacturing and quality control."
As the leader in cell therapy services, Cognate BioServices anticipates rapid growth within the cell-based service industry. Please visit their website, http://www.cognatebioservices.com, for further information.
About Cognate BioServices
Cognate BioServices, Inc. is a fully integrated contract bioservices organization providing the highest level of scientific and management expertise to its clients who are focused on the commercialization of cell- based products. Its comprehensive service package supports new and developing companies in the specific areas of preclinical research, assay development, regulatory services, process development, cGMP cell-based manufacturing, environmental health & safety, and laboratory support services. In addition to the corporate headquarters in Baltimore, Maryland, Cognate BioServices operates a GMP manufacturing facility in Sunnyvale, California. For more information visit the company's website at http://www.cognatebioservices.com.
Cognate BioServices, Inc.
CONTACT: Aaron Heifetz of Cognate BioServices, +1-410-455-5641 email@example.com